Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year revenue growth rate
Latest
0.00%
↓ 100% vs avg
Percentile
P49
Within normal range
Average
438.16%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | -100.00% |
| Q4 2024 | -22.89% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | -100.00% |
| Q4 2023 | 141.95% |
| Q3 2023 | -63.30% |
| Q2 2023 | 35.37% |
| Q1 2023 | -46.99% |
| Q4 2022 | -94.01% |
| Q3 2022 | 1347.14% |
| Q2 2022 | -11.94% |
| Q1 2022 | 435.62% |
| Q4 2021 | -83.78% |
| Q3 2021 | -59.76% |
| Q2 2021 | 609.30% |
| Q1 2021 | -68.40% |
| Q4 2020 | 34.74% |
| Q3 2020 | -16.97% |
| Q2 2020 | -51.42% |
| Q1 2020 | 131.57% |
| Q4 2019 | -255.41% |
| Q3 2019 | 26.16% |
| Q2 2019 | -17.78% |
| Q1 2019 | 8.57% |
| Q4 2018 | 22.32% |
| Q3 2018 | -14.84% |
| Q2 2018 | 6.74% |
| Q1 2018 | 100.70% |
| Q4 2017 | -91.08% |
| Q3 2017 | 15766.66% |
| Q2 2017 | -58.93% |
| Q1 2017 | 111.10% |
| Q4 2016 | -43.39% |
| Q3 2016 | -50.58% |
| Q2 2016 | 0.00% |
| Q1 2016 | 0.00% |